A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor

Paul A Foster, Surinder K Chander, Simon P Newman, L W Lawrence Woo, Oliver B Sutcliffe, Christian Bubert, Dujin Zhou, Shiuan Chen, Barry V L Potter, Michael J Reed, Atul Purohit

    Research output: Contribution to journalArticlepeer-review

    34 Citations (Scopus)

    Abstract

    The production of E2 is paramount for the growth of estrogen receptor-positive breast cancer. Various strategies have been used, including the use of enzyme inhibitors against either aromatase (AROM) or steroid sulfatase (STS), in an attempt to ablate E2 levels. Both these enzymes play a critical role in the formation of estrogenic steroids and their inhibitors are now showing success in the clinic.
    Original languageEnglish
    Pages (from-to)6469-77
    Number of pages9
    JournalClinical Cancer Research
    Volume14
    Issue number20
    DOIs
    Publication statusPublished - 2008

    Fingerprint

    Dive into the research topics of 'A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor'. Together they form a unique fingerprint.

    Cite this